[{"orgOrder":0,"company":"Labcorp","sponsor":"Xcell Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Labcorp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Labcorp \/ Xcell Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Labcorp \/ Xcell Biosciences"},{"orgOrder":0,"company":"Labcorp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Fidanacogene elaparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Labcorp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Labcorp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Labcorp \/ Inapplicable"},{"orgOrder":0,"company":"Labcorp","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Labcorp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Labcorp \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Labcorp \/ Amgen Inc"}]

Find Clinical Drug Pipeline Developments & Deals by Labcorp

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : The FDA has approved its nAbCyte Anti-AAVRh74var HB-FE Assay, a companion diagnostic to determine patient eligibility for treatment with Beqvez (fidanacogene elaparvovec).

Product Name : Beqvez

Product Type : Cell and Gene therapy

Upfront Cash : Inapplicable

April 29, 2024

Lead Product(s) : Fidanacogene elaparvovec

Therapeutic Area : Genetic Disease

Highest Development Status : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

02

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : Through the collaboration, Labcorp and Xcellbio will work on a series of projects focused on improving the safety and efficacy of cell and gene therapies (CGTs). s. The projects included in the collaboration will use Xcellbio’s AVATAR incubator system ...

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : Undisclosed

April 19, 2022

Lead Product(s) : Undisclosed

Therapeutic Area : Oncology

Highest Development Status : Preclinical

Sponsor : Xcell Biosciences

Deal Size : Undisclosed

Deal Type : Collaboration

blank

03

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : Using the lung biopsy specimen, the assay identifies whether a patient with NSCLC has a specific mutation in the KRAS gene and is eligible for treatment with LUMAKRAS™ (sotorasib) which was developed by Amgen.

Product Name : Lumakras

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

January 07, 2021

Lead Product(s) : Sotorasib

Therapeutic Area : Oncology

Highest Development Status : Approved FDF

Sponsor : Amgen Inc

Deal Size : Inapplicable

Deal Type : Inapplicable

blank